FILE PHOTO: The new Apple iPhone, the X is seen to be on display at the Apple Store in midtown Manhattan, New York, New York, united states of america, September 21, 2018. REUTERS/Shannon Stapleton
(Reuters) – Drugmaker Eli Lilly said Thursday that the early results of the study show that the Apple Inc. devices, including the iPhone, in conjunction with the digital apps, can a distinction be made between people with mild Alzheimer’s disease, dementia, and those with no symptoms at all.
In the study, was tested in 113 of the participants are over the age of 60 years old, and that it was done by Apple, along with Eli Lilly and Evidation Health.
Apple’s devices have been used, together with the Beddit sleep monitoring device and digital applications in the study.
The researchers looked at the use of the device, the data and the apps in the history of the participants in the study for more than 12 weeks.
People with symptoms have a tendency to be slower to type in than the health of the volunteers, and receive fewer sms messages in total.
The participants were also asked to provide the answers to the first two questions, surveys conducted on a daily, as well as the execution of a simple activity for the next two weeks, as the drag from one shape to another, and tapping on a circle, so that it is possible for a mobile app.
The study also aimed to discriminate between people with mild cognitive impairment, a pre-stage of dementia of the Alzheimer’s disease.
The first results of which were presented at a conference in Alaska on Thursday.
Report by Manas Mishra in Bengaluru; Editing by shailesh Kuber